Forxiga CKD Japan Post-Marketing Surveillance (PMS)

Study identifier:D169AC00007

ClinicalTrials.gov identifier:NCT05306210

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Forxiga tablets 5mg, 10mgGeneral Drug Use-Results Study n in chronic kidney disease (CKD) patients

Medical condition

Chronic Kidney Disease

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

1029

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 12 Apr 2022
Estimated Primary Completion Date: 16 Apr 2025
Estimated Study Completion Date: 16 Apr 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria